Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55.

Article  CAS  Google Scholar 

WHO. Global priority list of antibiotic resistant bacteria to guide research discovery and development of new antibiotics 2017 Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.

xWHO. Antimicrobial resistance 2021 Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.

Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–18.

Article  PubMed  PubMed Central  Google Scholar 

Wu D, Wu C, Zhang S, Zhong Y. Risk factors of ventilator-associated pneumonia in critically III patients. Front Pharmacol. 2019;10:482.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monegro AF, Muppidi V, Regunath H. Hospital acquired infections. Treasure Island, FL: StatPearls Publishing; 2022.

Ayobami O, Brinkwirth S, Eckmanns T, Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low-and lower-middle-income countries: a systematic review and meta-analysis. Emerg Microbes Infect. 2022;11:443–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903–10.

Baron S, Hadjadj L, Rolain J-M, Olaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents. 2016;48:583–91.

Article  CAS  PubMed  Google Scholar 

Chung WY, Abdul Rahim N, Mahamad Maifiah MH, Hawala Shivashekaregowda NK, Zhu Y, Wong EH. In silico genome-scale metabolic modeling and in vitro static time-kill studies of exogenous metabolites alone and with polymyxin B against Klebsiella pneumoniae. Front Pharmacol. 2022;13:880352.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggarwal R, Dewan A. Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17:1–8.

Article  Google Scholar 

Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, et al. Optimizing polymyxin combinations against resistant Gram-negative bacteria. Infect Dis Ther. 2015;4:391–415.

Article  PubMed  PubMed Central  Google Scholar 

Abdul Rahim N, Cheah S-E, Johnson MD, Yu H, Sidjabat HE, Boyce J, et al. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’antibiotics—polymyxin B and chloramphenicol. J Antimicrob Chemother. 2015;70:2589–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olsson A, Wistrand-Yuen P, Nielsen EI, Friberg LE, Sandegren L, Lagerbäck P, et al. Efficacy of antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in automated time-lapse microscopy and static time-kill experiments. Antimicrob Agents Chemother. 2020;64:e02111–19.

Article  PubMed  PubMed Central  Google Scholar 

Dinos GP, Athanassopoulos CM, Missiri DA, Giannopoulou PC, Vlachogiannis IA, Papadopoulos GE, et al. Chloramphenicol derivatives as antibacterial and anticancer agents: historic problems and current solutions. Antibiotics. 2016;5:20.

Article  PubMed  PubMed Central  Google Scholar 

Shukla P, Bansode F, Singh R. Chloramphenicol toxicity: a review. J Med Med Sci. 2011;2:1313–6.

Google Scholar 

Dong X, Yan X, Li M, Liu H, Li J, Wang L, et al. Ultrasensitive detection of chloramphenicol using electrochemical aptamer sensor: a mini review. Electrochem Commun. 2020;120:106835.

Article  CAS  Google Scholar 

Giguère S, Prescott JF, Dowling PM. Antimicrobial therapy in veterinary medicine. Hoboken, New Jersey, US: John Wiley & Sons; 2013.

Giannopoulou PC, Missiri DA, Kournoutou GG, Sazakli E, Papadopoulos GE, Papaioannou D, et al. New chloramphenicol derivatives from the viewpoint of anticancer and antimicrobial activity. Antibiotics. 2019;8:9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussein M, Hu X, Paulin OK, Crawford S, Zhou QT, Baker M, et al. Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens. Comput Struct Biotechnol J. 2020;18:2247–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance. Pathogens. 2021;10:165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan AU, Maryam L, Zarrilli R. Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol. 2017;17:1–12.

Article  Google Scholar 

Hudson CM, Bent ZW, Meagher RJ, Williams KP. Resistance determinants and mobile genetic elements of an NDM-1-encoding Klebsiella pneumoniae strain. PLoS ONE. 2014;9:e99209.

Article  PubMed  PubMed Central  Google Scholar 

Schjørring S, Struve C, Krogfelt KA. Transfer of antimicrobial resistance plasmids from Klebsiella pneumoniae to Escherichia coli in the mouse intestine. J Antimicrob Chemother. 2008;62:1086–93.

Article  PubMed  PubMed Central  Google Scholar 

Elliott AG, Ganesamoorthy D, Coin L, Cooper MA, Cao MD. Complete genome sequence of Klebsiella quasipneumoniae subsp. similipneumoniae strain ATCC 700603. Genome Announc. 2016;4:e00438–16.

Article  PubMed  PubMed Central  Google Scholar 

Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Doménech-Sánchez A, Swenson JM, et al. Characterization of the extended-spectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother. 2000;44:2382–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adamo A, Delfino P, Gatti A, Bonato A, Takam Kamga P, Bazzoni R, et al. HS-5 and HS-27A stromal cell lines to study bone marrow mesenchymal stromal cell-mediated support to cancer development. Front Cell Dev Biol. 2020;8:584232.

Article  PubMed  PubMed Central  Google Scholar 

Ezadi F, Ardebili A, Mirnejad R. Antimicrobial susceptibility testing for polymyxins: challenges, issues, and recommendations. J Clin Microbiol. 2019;57:e01390–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simar S, Sibley D, Ashcraft D, Pankey G. Colistin and polymyxin B minimal inhibitory concentrations determined by Etest found unreliable for Gram-negative bacilli. Ochsner J. 2017;17:239–42.

PubMed  PubMed Central  Google Scholar 

Bayot ML, Bragg BN. Antimicrobial susceptibility testing. Treasure Island, FL: StatPearls Publishing; 2022.

Google Scholar 

Rattanapanadda P, Kuo H-C, Vickroy TW, Sung C-H, Rairat T, Lin T-L, et al. In vitro and in vivo synergistic effects of florfenicol and thiamphenicol in combination against swine Actinobacillus pleuropneumoniae and Pasteurella multocida. Front Microbiol. 2019;10:2430.

Article  PubMed  PubMed Central  Google Scholar 

Cui Z-H, He H-L, Wu S-B, Dong C-L, Lu S-Y, Shan T-J, et al. Rapid screening of essential oils as substances which enhance antibiotic activity using a modified well diffusion method. Antibiotics. 2021;10:463.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He S, He H, Chen Y, Chen Y, Wang W, Yu D. In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii. Front Microbiol. 2015;6:507.

Article  PubMed  PubMed Central  Google Scholar 

Rao GG, Ly NS, Diep J, Forrest A, Bulitta JB, Holden PN, et al. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48:331–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei C-F, Shien J-H, Chang S-K, Chou C-C. Florfenicol as a modulator enhancing antimicrobial activity: example using combination with thiamphenicol against Pasteurella multocida. Front Microbiol. 2016;7:389.

Article  PubMed  PubMed Central  Google Scholar 

Silva F, Lourenço O, Queiroz JA, Domingues FC. Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye. J Antibiot. 2011;64:321–5.

Article  CAS  Google Scholar 

Anantharaman A, Rizvi MS, Sahal D. Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob Agents Chemother. 2010;54:1693–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kotzialampou A, Protonotariou E, Skoura L, Sivropoulou A. Synergistic antibacterial and antibiofilm activity of the MreB inhibitor A22 hydrochloride in combination with conventional antibiotics against Pseudomonas aeruginosa and Escherichia coli clinical isolates. Int J Microbiol. 2021;2021:1–17.

Tängdén T. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Upsala J Med Sci. 2014;119:149–53.

Article  PubMed  PubMed Central  Google Scholar 

Rigatto MH, Falci DR, Zavascki AP. Clinical use of polymyxin B. Polymyxin Antibiotics: From Laboratory Bench to Bedside. Cham, Switzerland: Springer; 2019. p. 197–218.

Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60:1206–15.

Article  CAS  PubMed  Google Scholar 

Pizzolato-Cezar LR, Okuda-Shinagawa NM, Machini MT. Combinatory therapy antimicrobial peptide-antibiotic to minimize the ongoing rise of resistance. Front Microbiol. 2019;10:1703.